Opendata, web and dolomites

LIsTEN SIGNED

β-Lactams as flaviviral NS3 protease inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIsTEN project word cloud

Explore the words cloud of the LIsTEN project. It provides you a very rough idea of what is the project "LIsTEN" about.

threat    moderate    denv    asia    united    possibility    synthesized    billion    mediterranean    reduce    warming    strategy    consist    valuable    lactams    natural    dengue    off    residue    treatment    wnv    diseases    unnatural    affinity    act    significantly    site    previously    accordingly    living    emerged    medical    covalent    disease    potent    lactam    moment    membrane    bond    assays    adriatic    warhead    active    exist    purpose    group    culture    consequence    global    amino    compounds    improvement    stability    infections    biochemical    electrophilic    ns3    inhibitor    west    tropical    virus    inhibitors    coast    near    enzyme    agents    serine    america    peptide    incorporation    people    ameliorate    inhibitory    coupled    sub    host    acids    climate    replication    metabolic    flaviviral    permeability    beta    cell    regions    catalytic    nile    zikv    spread    moiety    zika    protease    warheads    outbreak    derivatives    potency    selectivity    binding    parts   

Project "LIsTEN" data sheet

The following table provides information about the project.

Coordinator
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG 

Organization address
address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117
website: www.uni-heidelberg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.ipmb.uni-heidelberg.de/chemie/klein/drazic.html
 Total cost 171˙460 €
 EC max contribution 171˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-05-02   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) coordinator 171˙460.00

Map

 Project objective

Flaviviral infections already represent a threat to 2.5 billion people living in tropical and sub-tropical regions. As a consequence of climate change and global warming in the near future these infections are expected to spread to areas with moderate climate and the possibility of disease outbreak will exist in Europe, especially around the Mediterranean and Adriatic coast, as well as in the United States of America and large parts of Asia. At the moment no medical treatment against flaviviral diseases is available. Recently, peptide-based compounds which act as flaviviral NS3 protease inhibitors, emerged as potent agents against dengue virus (DENV), Zika virus (ZIKV) and West Nile virus (WNV). These compounds consist of two to four natural or unnatural amino acids and act by binding to the active site of the protease. Accordingly, the incorporation of an electrophilic warhead, a moiety which would facilitate the covalent binding of the inhibitor to the catalytic serine residue, into the peptide inhibitor represents a valuable strategy for the improvement of potency of such inhibitors. The goal of the proposed project is to investigate the potential of β-lactams as electrophilic warheads in DENV, ZIKV and WNV protease inhibitors. For that purpose, new β-lactam derivatives will be synthesized, coupled to peptide inhibitors previously developed by the host group and their affinity to the target will be evaluated by biochemical assays. The most potent compounds will be characterized in more detail and their activity against dengue virus replication in cell culture, off-target binding, membrane permeability and metabolic stability will be studied. We expect the formation of a covalent bond between inhibitor and active site of the enzyme to significantly improve inhibitory activity by increasing binding affinity, as well as to ameliorate selectivity and reduce off-target binding.

 Publications

year authors and title journal last update
List of publications.
2019 Tonko Dražić, Sara Kopf, James Corridan, Mila M. Leuthold, Branimir Bertoša, Christian D. Klein
Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes
published pages: 140-156, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00759
Journal of Medicinal Chemistry 63/1 2020-02-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LISTEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LISTEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

VINCI (2020)

The Value of Information and Choice to Improve Control.

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More  

STIMOS (2019)

Stimulation of Multiple Organoids Simultaneously

Read More